Harrow Inc Dossier
Qualitative Analysis
Business overview
Harrow, Inc. (NASDAQ: HROW) is a leading North American eyecare pharmaceutical company focused on the discovery, development, and commercialization of ophthalmic products. The company operates through two primary segments: Branded products and ImprimisRx compounding services. Its Branded portfolio features FDA-approved ophthalmic pharmaceuticals, including VEVYE (for dry eye disease), IHEEZO (ocular surface anesthesia), and TRIESENCE, alongside legacy Novartis assets and biosimilars like BYOOVIZ and OPUVIZ. The ImprimisRx segment operates as a high-volume, specialized compounding business serving eyecare professionals directly. Harrow has successfully transitioned from a pure-play compounding pharmacy into a high-margin, branded pharmaceutical business.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A company-wide initiative to unify all commercial operations, branding, and marketing under the single 'Harrow' brand (integrating ImprimisRx and Harrow).
Expected impact: Provides greater focus, tighter alignment, and a unified commercial effort to drive disciplined and coordinated execution across a single organization.
Hiring initiative to double the number of covered US territories for VEVYE from approximately 50 to 100.
Expected impact: Aims to fuel continued market-share expansion and accelerate prescription momentum for VEVYE in 2026 and beyond.
Expanding the commercial focus of IHEEZO beyond retina practices to the broader office-based ophthalmic procedures market.
Expected impact: Targets a market exceeding 2.5 million annual use cases to accelerate demand and drive new adoption across anesthesia-dependent, reimbursed procedures.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To acquire full ownership of Melt's clinical-stage pipeline, including MELT-300, a non-opioid, non-IV sublingual sedation drug candidate, allowing Harrow to enter the multi-billion-dollar procedural sedation and anxiety market.
Financial impact: Initial cash payment of $4.3 million at closing, with contingent consideration consisting of cash and equity (up to a potential $87 million earnout) upon achievement of regulatory and sales milestones. R&D expenses increased to support the integrated programs.
Strategic Partnerships
Secures exclusive U.S. commercial rights to Samsung Bioepis' ophthalmology biosimilar portfolio, including BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), positioning Harrow in the $9 billion U.S. retinal disease treatment market.
Terms: Financial terms of the agreement were not publicly disclosed.